Saharan horned viper venom toxins (C. cerastes venom)

Snake venom toxins from Cerastes cerastes, commonly known as the Saharan horned viper, consist of a complex pharmacological cocktail of proteins and peptides that primarily disrupt the hemostatic and cardiovascular systems of the victim (UniProt, 2023). The venom is characterized by high concentrations of snake venom metalloproteinases (SVMPs), which degrade the basement membrane of blood vessels leading to systemic hemorrhage, and phospholipases A2 (PLA2s), which induce inflammation and myotoxicity (PubMed, PMID: 31635255). Additionally, the venom contains serine proteases that act as thrombin-like enzymes or activators of coagulation factors, often resulting in venom-induced consumptive coagulopathy (VICC). While these toxins are the primary cause of pathology in envenomation, they serve as therapeutic targets for polyvalent antivenoms and are being researched as sources for novel drug leads in hematology. Modern therapeutic strategies also explore the use of small-molecule inhibitors like varespladib to neutralize specific enzymatic components such as PLA2 in the field (NIH/NCBI, 2021). This target entry is marked as incorrect/broad because it represents a heterogeneous mixture of multiple distinct protein families rather than a single molecular entity.

Other names

Cerastes cerastes venomHorned desert viper toxinsCerastes cerastes snake venom proteins

Therapeutic intervention involves the use of antivenom antibodies that bind and sequester toxins to prevent their interaction with host substrates, or small-molecule inhibitors that bind to the active sites of enzymatic toxins like PLA2 and metalloproteinases.